Neil Vasan, Director of Breast Cancer Translational Research at NYU Langone Health, shared on X:
“PDAC patients and Revolution Medicines benefited uniquely from the priority voucher program.
Daraxonrasib (RASONQUE) was approved in 35 days, 6.5 months ahead of schedule.
It’s approved today. Without the voucher, it wouldn’t be until March 2027.”
Read more: FDA appears to pause controversial speedy review program, complete response letter disclosures.”
You can also read: The Promise of Daraxonrasib: The Price of Progress in Pancreatic Cancer – Common Sense Oncology.
